Ion Exchange India Q1-FY27 Results

Consolidated Operating Income: ₹700.5 crore
Consolidated PAT: ₹3.1 crore

Reader Takeaway: Strong revenue growth across segments faces margin pressures from legacy projects and external factors.

What Just Happened

Ion Exchange (India) has announced its financial results for the first quarter of FY27. The company reported consolidated operating income of ₹700.5 crore. However, consolidated Profit After Tax (PAT) stood at ₹3.1 crore. On a standalone basis, the company reported operating income of ₹635.6 crore and PAT of ₹11.4 crore.

The company's total order book was ₹2,473 crore, with a bid pipeline of ₹9,777 crore as of June 30, 2026.

Why This Matters

The results highlight a contrast between strong revenue generation and subdued profitability. While revenue growth was seen across most segments, including Consumer Products (33%) and Industrial Products (14%), the company's margins were squeezed. This is attributed to ongoing issues with legacy projects in the Treatment Solutions segment and geopolitical impacts and costs at the Roha facility affecting the Specialty Chemicals segment.

The Backstory

Ion Exchange (India) operates in water and environment management solutions. The company has been working on clearing existing backlogs and expanding into new markets. The Roha facility is a significant investment aimed at bolstering its Specialty Chemicals division.

What Changes Now

Management is focused on executing the existing order book and leveraging new business opportunities. The performance of the Roha facility and the successful resolution of legacy project issues will be critical for improving profitability going forward.

Risks to Watch

Margin pressures from legacy projects and geopolitical impacts remain a key concern. Investors will be watching the ramp-up and cost-efficiency of the new Roha facility, which is crucial for the Specialty Chemicals segment's future margins.

Peer Comparison

While specific peer results for Q1-FY27 are not detailed in the filing, the company operates in the water treatment and specialty chemicals sectors, competitive industries with varying margin profiles depending on project execution and raw material costs.

Context Metrics

Consolidated EBITDA Margin: 4.54% (Q1-FY27)
Standalone PAT Margin: 1.79% (Q1-FY27)
Treatment Solutions Revenue Growth: 14%
Specialty Chemicals Revenue Growth: 21%
Consumer Products Revenue Growth: 33%

What to Track Next

Investors should monitor the company's progress in liquidating its ₹2,473 crore order book, the successful operationalization and cost management at the Roha facility, and the resolution of issues impacting legacy projects. Performance of the Industrial Products and Lifecycle Services segments will also be key indicators.